Research Associate/Fellow (Fixed-Term): The University of Nottingham is seeking a dedicated and innovative Research Associate/Fellow to join a research project focused on evaluating the effects of novel peptide-siRNA conjugated therapeutics on chronic pain and inflammation in osteoarthritic joints. This research is funded by Arthritis UK and will support defined objectives related to pain and inflammation in osteoarthritis.
Designation
Research Associate/Fellow (Fixed-Term)
Table
| Details | Information |
|---|---|
| Research Area | Life Sciences |
| Location | University Park, University of Nottingham |
| Salary | £31,387 to £46,485 per annum, dependent on skills and experience |
| Closing Date | Friday, 3rd April 2026 |
| Funding Duration | 24 months |
Eligibility/Qualification
- Relevant PhD in Life Sciences or a related field.
- Experience in in vivo research or related methodologies is desirable.
Job Description
The primary focus of this role is to evaluate the in vivo efficacy of novel peptide-siRNA conjugate therapeutics aimed at reducing joint pain and inflammation in osteoarthritis. Responsibilities include:
- Conducting in vivo behavioral and physiological assessments in animal models.
- Collaborating with a multidisciplinary team.
- Writing publications based on research findings.
- Identifying new research avenues and refining methodologies.
The role is supervised by Prof. Victoria Chapman, Associate Prof. Federico Dajas-Bailador, and Research Fellow Kim Chisholm, all of whom bring extensive experience in relevant areas.
How to Apply
Interested candidates should send a cover letter and CV to:
- Prof. Victoria Chapman (victoria.chapman@nottingham.ac.uk)
- Dr. Federico Dajas-Bailador (F.Dajas-Bailador@nottingham.ac.uk)
- Dr. Kim Chisholm (kim.chisholm@nottingham.ac.uk)
Visit the University of Nottingham job page for more details on application procedures.
Last Date to Apply
Friday, 3rd April 2026
For further information, please review the guidelines provided by the university or reach out to the supervisors listed above.
